Almirall Revenue and Competitors
Estimated Revenue & Valuation
- Almirall's estimated annual revenue is currently $490.2M per year.
- Almirall's estimated revenue per employee is $201,000
Employee Data
- Almirall has 2439 Employees.
- Almirall grew their employee count by 6% last year.
Almirall's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | CFO Executive Assistant | Reveal Email/Phone |
4 | Head Sales UK and Ireland | Reveal Email/Phone |
5 | Head Disease Biology | Reveal Email/Phone |
6 | Head Data & Analytics | Reveal Email/Phone |
7 | Head Market Access, Nordics | Reveal Email/Phone |
8 | General Counsel | Reveal Email/Phone |
9 | Head Sales, Pharmacy Channel and Communications | Reveal Email/Phone |
10 | Head Preclinical Safety | Reveal Email/Phone |
Almirall Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $252.7M | 1257 | 11% | N/A | N/A |
What Is Almirall?
Almirall is a global company based in Barcelona dedicated to providing valuable medicines and medical devices through its R&D, agreements and alliances. Our work covers the whole of the drug value chain. A consolidated growth allows us to devote our talent and efforts towards specialty areas and particularly to further grow as a leading Dermatology player. We are a specialist company, enabling us to accomplish the purpose of taking our innovative products wherever they are needed. Founded in 1943, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totalled 859.3 million euros and, with more than 1,900 employees, it has gradually built up a trusted presence across Europe, as well as in the US. For more information, please visit www.almirall.com. Dermatology (Actinic keratosis, Atopic Dermatitis, Eczema, Inflammatory Skin Conditions, Psoriasis, Rosacea, Severe Acne), OTC Products, Aesthetics, Other Specialty Areas (e.g. Spasticity in Multiple Sclerosis)
keywords:N/A
N/A
Total Funding
2439
Number of Employees
$490.2M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Almirall News
Almirall: Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis.
Almirall and University of Dundee announce a collaboration to develop a novel treatment to fully control itch in skin diseases and achieve a...
The case arose in an inter partes review (IPR) proceeding by challenger Amneal over Almirall's U.S. Patent No. 9,517,219.
Almirall launches "Shedding Light on Psoriasis" campaign to raise awareness on World Psoriasis Day 28 October 2021 The campaign aims to raise awareness on how psoriasis deeply impacts the wellbeing of people living with this long-term condition and their families Psoriasis represents a signifi ...
Almirall launches Klisyri®▼(tirbanibulin) for the treatment of actinic keratosis in Europe 27 September 2021 The UK and Germany are the first two European countries where Klisyri® will be available for prescription. The product has been approved for the treatment of actinic keratosis by the UK ...
Other Companies in Columbus
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1660M | 2450 | -10% | N/A |
#2 | $627.5M | 2490 | N/A | N/A |
#3 | $300M | 2540 | 11% | N/A |
#4 | $524.6M | 2584 | -5% | N/A |
#5 | $1287.9M | 2606 | N/A | N/A |